NanoString Technologies Inc (NSTG):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:NanoString Technologies Inc (NSTG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8018
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NanoString Technologies Inc (NanoString) is a developer of life science tools for translational research and molecular diagnostics. The company’s products include sprint profiler, Dx analysis system with flex, nCounter MAX analysis system, protein assays, solid tumor assays, gene fusion panels, RNA panels, DNA assays, immunology panel, gene expression codesets, pancancer immune profiling and pathways, among others. Its nCounter MAX analysis system provides cost-effective method to profile various miRNA, miRGE or DNA molecules simultaneously employing a novel digital molecular barcoding technology. The company sells its products through direct sales force and distributors in Austria, Poland, Czech Republic, Slovakia, Hungary, Croatia, Slovenia, Bosnia Herzegovina, Serbia, Romania, Albania, Macedonia and Bulgaria, among others. NanoString is headquartered in Seattle, Washington, the US.

NanoString Technologies Inc (NSTG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NanoString Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NanoString Technologies Inc, Medical Devices Deals, 2012 to YTD 2018 10
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
NanoString Technologies Raises US$0.2 Million In Venture Financing 12
NanoString Technologies Raises US$15 Million In Series E Financing 13
NanoString Technologies To Raise US$0.65 Million In Venture Financing 15
Partnerships 16
NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 16
NanoString Enters into Research Agreement with CITN for Novel Cancer Immunotherapies 17
NanoString Enters into Co-Development Agreement with Celgene 18
NanoString Technologies And BD Biosciences Enter Into Agreement To Develop Single Cell Isolation And Analysis Workflow 19
Licensing Agreements 20
NanoString Technologies Enters Into Option For Licensing Agreement With Massachusetts General Hospital 20
Equity Offering 21
NanoString Technologies Completes Underwriters Exercise of Over-Allotment Option of Public offering of Shares of Shares for USD57.5 Million 21
NanoString Technologies Plans to Raise up to USD40 Million in Private Placement of Shares 23
NanoString Technologies Completes Public Offering Of Shares For US$55 Million 24
NanoString Technologies Completes IPO Of Shares For US$54 Million 26
NanoString Technologies Inc – Key Competitors 28
NanoString Technologies Inc – Key Employees 29
NanoString Technologies Inc – Locations And Subsidiaries 30
Head Office 30
Recent Developments 31
Financial Announcements 31
Aug 07, 2018: NanoString Technologies Releases Operating Results for Second Quarter of 2018 31
Jul 16, 2018: NanoString Technologies Provides Preliminary Revenue Results for Second Quarter 2018 33
May 08, 2018: NanoString Technologies Releases Operating Results for First Quarter of 2018 34
Jan 08, 2018: NanoString Technologies Provides Preliminary Operational and Financial Results for Fourth Quarter and Fiscal Year 2017 36
Nov 02, 2017: NanoString Technologies Releases Operating Results for Third Quarter of 2017 37
Oct 11, 2017: NanoString Announces Preliminary Revenue for Third Quarter of Fiscal Year 2017 38
Aug 08, 2017: NanoString Technologies Releases Operating Results for Second Quarter of 2017 39
May 04, 2017: NanoString Technologies Releases Operating Results for First Quarter of 2017 40
Mar 01, 2017: NanoString Technologies Releases Fourth Quarter and Full Year 2016 Operating Results and Provides 2017 Outlook 41
Jan 10, 2017: NanoString Technologies Provides Preliminary Operational and Financial Results for 2016 42
Corporate Communications 43
May 10, 2017: NanoString Appoints Elisha W. Finney to Board of Directors 43
Product News 44
Apr 03, 2017: Digital Spatial Profiling Technology Enables Quantitative Protein Profiling in FFPE Tissue Providing Detailed Molecular Characterization of Immune Response to Tumors 44
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NanoString Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NanoString Technologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9
NanoString Technologies Inc, Medical Devices Deals, 2012 to YTD 2018 10
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
NanoString Technologies Raises US$0.2 Million In Venture Financing 12
NanoString Technologies Raises US$15 Million In Series E Financing 13
NanoString Technologies To Raise US$0.65 Million In Venture Financing 15
NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 16
NanoString Enters into Research Agreement with CITN for Novel Cancer Immunotherapies 17
NanoString Enters into Co-Development Agreement with Celgene 18
NanoString Technologies And BD Biosciences Enter Into Agreement To Develop Single Cell Isolation And Analysis Workflow 19
NanoString Technologies Enters Into Option For Licensing Agreement With Massachusetts General Hospital 20
NanoString Technologies Completes Underwriters Exercise of Over-Allotment Option of Public offering of Shares of Shares for USD57.5 Million 21
NanoString Technologies Plans to Raise up to USD40 Million in Private Placement of Shares 23
NanoString Technologies Completes Public Offering Of Shares For US$55 Million 24
NanoString Technologies Completes IPO Of Shares For US$54 Million 26
NanoString Technologies Inc, Key Competitors 28
NanoString Technologies Inc, Key Employees 29

List of Figures
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NanoString Technologies Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[NanoString Technologies Inc (NSTG):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Boston Consulting Group:企業の戦略・SWOT・財務情報
    The Boston Consulting Group - Strategy, SWOT and Corporate Finance Report Summary The Boston Consulting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • ABM Industries Incorporated (ABM):企業の財務・戦略的SWOT分析
    ABM Industries Incorporated (ABM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Burmeister & Wain Scandinavian Contractor AS:企業の戦略的SWOT分析
    Burmeister & Wain Scandinavian Contractor AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Pine Cliff Energy Ltd (PNE):企業の財務・戦略的SWOT分析
    Summary Pine Cliff Energy Ltd (Pine Cliff) is an oil and gas company that offers exploration, production, and development of natural gas, crude oil, and natural gas liquids. The company operates through its core areas such as Edson Assets, Central Assets, and Southern Assets. It acquired Hatton prop …
  • Msig Holdings (Asia) Pte. Ltd.
    Msig Holdings (Asia) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Msig Holdings (Asia) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Royal IHC:石油・ガス:M&Aディール及び事業提携情報
    Summary Royal IHC (IHC), formerly IHC Merwede BV is a shipbuilding company that offers engineering solutions. The company’s product portfolio includes dredging equipment, motion control and automation equipment, decommissioning equipment, offshore foundation equipment and metal construction kits. IH …
  • Isagenix International LLC:企業の戦略的SWOT分析
    Isagenix International LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • NGEx Resources Inc:企業のM&A・事業提携・投資動向
    NGEx Resources Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NGEx Resources Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • MaaT Pharma:製薬・医療:M&Aディール及び事業提携情報
    Summary MaaT Pharma (MaaT) is a biotechchnology company that develop novel treatments for Gut Microbiota - dysbiosis related diseases. The company focuses on developing MaaT001, an innovative live frozen inoculum suspension and MaaT002, an innovative device for stool collection and storage. It also …
  • Energy Recovery Inc (ERII):企業の財務・戦略的SWOT分析
    Energy Recovery Inc (ERII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Nishat Mills Ltd:企業の戦略・SWOT・財務情報
    Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report Summary Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Aratana Therapeutics Inc (PETX):企業の財務・戦略的SWOT分析
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …
  • ANI Technologies Pvt Ltd:企業の戦略的SWOT分析
    ANI Technologies Pvt Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Episurf Medical AB (EPIS B):企業の製品パイプライン分析
    Summary Episurf Medical AB (Episurf Medical), formerly Diamorph Medtech AB is a medical technology company that provides patient-specific treatments of painful joint injuries. It offers diagnosis and design of implants and surgical instruments. Its products include Episealer Femoral Twin, Episealer …
  • Emerson Electric Co (EMR):企業の財務・戦略的SWOT分析
    Emerson Electric Co (EMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Retail Food Group Limited (Foodservice):企業の戦略・SWOT・財務分析
    Retail Food Group Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Retail Food Group Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Ceres Nanosciences Inc:製品パイプライン分析
    Summary Ceres Nanosciences Inc (Ceres Nanosciences) is a provider of sample preparation products and diagnostic tests. The company offers Nanotrap particles for research and development and Nanotrap lyme antigen test that are protein enrichment toolset that can be integrated seamlessly into any exis …
  • Cypress Semiconductor Corporation (CY):企業の財務・戦略的SWOT分析
    Cypress Semiconductor Corporation (CY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Mount Tam Biotechnologies Inc (MNTM)-製薬・医療分野:企業M&A・提携分析
    Summary Mount Tam Biotechnologies Inc (Mount Tam Biotechnologies), a subsidiary of TabacaleraYsidron Inc is a provider of pharmaceutical products that focuses on the development and commercialization of medical compounds for autoimmune diseases. The company’s lead product candidate TAM-0, a rapamyci …
  • Islami Bank Bangladesh Ltd
    Islami Bank Bangladesh Ltd - Strategy, SWOT and Corporate Finance Report Summary Islami Bank Bangladesh Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆